Bal Pharma growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+2.8%+0.8%
EBITDA+7.9%+8.3%
Net Income−12.3%+34.1%
EPS (adj.)−12.9%+33.9%
Total Assets+11.9%+6.2%
Total Equity+6.3%+8.9%
Free Cash Flow−40.8%−18.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

BALPHARMA₹84.61

Bal Pharma Limited

· Pharma & Health
₹ CrorePeersALPAKREBSBIONATCAPSUQVINEETLABNECLIFEAAREYDRUGSBIOFILCHEMMANGALAMMcap ₹135 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+2.8+0.8
EBITDA+7.9+8.3
Net Income-12.3+34.1
EPS (adj.)-12.9+33.9
Total Assets+11.9+6.2
Total Equity+6.3+8.9
Free Cash Flow-40.8-18.9
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.